Monoclonal Anti-RSV-post-F0 specific Antibody, Human IgG1 (1A2D9D8) (MALS verified)

Human respiratory syncytial virus (HRSV) is the most common etiological agent of acute lower respiratory tract disease in infants and can cause repeated infections throughout life. The RSV fusion glycoprotein (RSV F) is the principal target of RSV neutralizing antibodies in human sera. The RSV F is a type I viral fusion protein synthesized as inactive, single-chain polypeptides that assemble into trimers. RSV F fuses the viral and host cell membranes by irreversible protein refolding from the labile prefusion conformation to the stable post-fusion conformation.

Product Specifications

Background

CAS Number

9007-83-4

Host

HEK293

Origin Species

Human

Target

Postfusion glycoprotein F0/post-F protein (RSV)

Conjugation

Unconjugated

Tag

Human IgG1 | Human Kappa

Stability

-20°C to -70°C for 12 months in lyophilized state; -70°C for 3 months under sterile conditions after reconstitution. For long term storage, the product should be stored at lyophilized state at -20°C or lower. Please avoid repeated freeze-thaw cycles.

Purity

0.9

Bioactivity

Immobilized HRSV (A) Post-fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H6) at 1 μg/mL (100 μL/well) can bind Monoclonal Anti-RSV-post-F0 specific Antibody, Human IgG1 (1A2D9D8) (Cat. No. RSV-M662) with a linear range of 0.1-16 ng/mL. HRSV (A) Pre-fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H7) is verified not recoginized by Monoclonal Anti-RSV-post-F0 Antibody, Human IgG1 (1A2D9D8) (Cat. No. RSV-M662) in low concentration (QC tested).